Completed PHASE3 INTERVENTIONAL NCT00076388

Iressa Versus Docetaxel (Taxotere)

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Sponsor: AstraZeneca

Conditions Non-Small-Cell Lung Carcinoma

Interventions Docetaxel Gefitinib

Updated 6 times since 2017 Last updated: May 12, 2011 Started: Feb 29, 2004 Primary completion: Mar 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00076388, this PHASE3 trial focuses on Non-Small-Cell Lung Carcinoma and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Ankara, Turkey (Türkiye) , Arhus C, Denmark , Austin, United States , Bad Segeberg, Germany , Barcelona, Spain , Bari, Italy , Beijing, China , Bellinzona, Switzerland , Bergamo, Italy and 152 more locations